Spring Symposium 2014: What’s New in Pharmacy?

Tuesday, May 13, 2014 (5:30pm – 9:30pm)

Duke Hospital Amphitheater (located in Duke South by the Food Court)

A Knowledge-Based Educational Symposium Sponsored by Duke University Hospital Department of Pharmacy

Registration/Light Dinner/Welcome
5:30pm – 6:00pm

Hypertension Management: An Update on JNC 8
Rachel Rogers, PharmD: PGY1 Pharmacy Practice Resident
6:00pm – 6:30pm

At the conclusion of this knowledge-based presentation, the participant should be able to:
1.) Compare major updates to the hypertension guidelines to historical goals and treatment of patients as outlined by JNC 7
2.) Summarize evidence supporting the recommendations for changes in treatment goals and initial pharmacologic therapy in the updated guidelines

New Pharmacologic Agents
Cathy Vaughan, PharmD: Clinical Pharmacist, Center for Medication Policy and Sarah White, PharmD: PGY2 Drug Information Resident
6:30pm – 7:30pm

At the conclusion of this knowledge-based presentation, the participant should be able to:
1.) Identify newly approved medications which offer pharmacotherapeutic advances
2.) Discuss clinical applications for each agent and compare with standard medications
3.) Identify important drug-drug interactions, adverse effects, and other safety issues
4.) List patient counseling information and monitoring parameters for each new medication

Break
7:30pm – 7:45pm
Updates in Anticoagulation: Edoxaban and Four-Factor Prothrombin Complex Concentrate

Doug Raiff, PharmD, BCPS: Clinical Pharmacist, Center for Medication Policy
7:45pm – 8:15pm

At the conclusion of this knowledge-based presentation, the participant should be able to:
1.) Compare and contrast the mechanism of action of edoxaban with other novel oral anticoagulants
2.) Given a patient weight and INR, provide an appropriate dose and administration rate of four-factor prothrombin complex concentrate

Managing the Unmanageable: Monitoring and Reversing New Oral Anticoagulants

Kimberly Hodulik, PharmD, CACP: Clinical Pharmacist, Anticoagulation
8:15pm – 8:45pm

At the conclusion of this knowledge-based presentation, the participant should be able to:
1.) Review measurement of anticoagulant effect of novel oral anticoagulants (NOACs)
2.) Discuss management of bleeding complications from NOAC therapy

2013 ACC/AHA Lipid Guidelines: Review and Critique

Lindsey Burgess, PharmD, BCPS: PGY2 Cardiology Resident and
Michelle Cefaretti, PharmD: PGY2 Ambulatory Care Resident
8:45pm – 9:15pm

At the conclusion of this knowledge-based presentation, the participant should be able to:
1.) Compare the components of the Pooled Cohort Equation to those of the Framingham Risk Assessment
2.) Analyze the benefits and limitations of the 2013 ACC/AHA recommendations for lipid management

Closing and Program Evaluation
9:15pm – 9:30pm

Opportunities for Q&A will be provided at the conclusion of each presentation.

The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CME activity: Rachel Rogers, PharmD, Cathy Vaughan, PharmD, Sarah White, PharmD, Doug Raiff, PharmD, Kimberly Hodulik, PharmD, Lindsey Burgess, PharmD, Michelle Cefaretti, PharmD, David Warner, PharmD, Kevin Helmlinger, PharmD
Program Goals: At the conclusion of this activity, learners should be able to:

1.) To review recently-updated disease management guidelines for hypertension and dyslipidemia.  
2.) To increase understanding of recent pharmacotherapy developments and how they impact patient care.

Target Audience

Pharmacists, pharmacy technicians, nurses, physicians, and mid-level practitioners.

Location

Duke University Medical Center Amphitheater (Duke South, Room 0916) 5:30pm – 9:30pm

Program Coordinators

Doug Raiff, PharmD, BCPS  
Clinical Pharmacist, Center for Medication Policy

Kevin Helmlinger, PharmD, BCPS  
PGY2 Health-System Pharmacy Administration Resident (Program Moderator)

David J. Warner, PharmD  
Associate Chief Pharmacy Officer, Duke University Hospital

Registration

Please pre-register for the 2014 Spring Symposium via email (name, address, occupation, type of CE credit requested, CE identification number and pin (if applicable), Duke Unique ID#) to doug.raiff@dm.duke.edu by May 2, 2014. On-site registration will be available, but food is only guaranteed to pre-registrants only. Registration will be capped at 150 attendees (room capacity). Presentation handouts will be available on the Duke Pharmacy internet website prior to the event for attendees to print.

Tuition

DUHS Employees: Free! (Registration must be completed by Friday, May 2, 2014)
Pre-Registration (non-DUHS Employees): $20 (Registration must be completed by Friday, May 2, 2014)
On-site Registration (DUHS Employees and non-Employees): $20

If you need any auxiliary aids or services identified in The Americans with Disabilities Act in order to attend this program, please call (919) 684-2414.
Duke School of Medicine requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved): and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medication education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. **The following off-label uses are discussed:**

- **Edoxaban is currently unapproved in the United States (evaluation by the FDA is ongoing).**
- **Methods of reversing the novel oral anticoagulants (NOACs) are currently not formally indicated by the FDA at this time. Currently, there are no FDA-approved agents to reverse NOACs.**

**Continuing Education Credit**

Duke Medicine is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

**Physicians:** Duke Medicine designates this live activity for a maximum of 3.25 **AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**Nurses:** This program is designated for 3.25 hours. Duke Medicine is approved by the ANCC, for 3.25 contact hours.

**Pharmacists:** Duke Medicine designates this activity for a maximum of 3.00 ACPE credit hours. **Universal Activity Number: 00851-0000-14-013-L01-P.** To Receive CE credit, attendance must be acknowledged at the registration desk upon arrival at and departure of the program. Statements of credit can be viewed and printed from CPE Monitor. The process of uploading continuing education credit to the CPE monitoring site can take up to 4 weeks after the event.